First-In-Human Study Evaluating Safety of JNJ-6420 for mCRPC

Michael Morris, MD, of Memorial Sloan Kettering Cancer Center, discusses a phase 1 study of JNJ-6420, an actinium-22-labeled antibody targeting human kallikrein 2, for metastatic castration-resistant prostate cancer.

In this first-in-human study, Dr. Morris and colleagues evaluating JNJ-6420 in heavily pretreated biomarker-unselected participants who received at least prior androgen receptor pathway inhibitor.